| Prev Close | 79.40 |
| Open | 80.02 |
| Day Low/High | 79.77 / 81.42 |
| 52 Wk Low/High | 41.76 / 92.98 |
| Volume | 600.64K |
| Avg Volume | 827.40K |
| Exchange | NASDAQ |
| Shares Outstanding | 89.88M |
| Market Cap | 7.03B |
| EPS | -1.60 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.
'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.
Neurocrine Plans to File the NDA During the First Half of 2019
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
A roundup of biotech names with actions pending at the FDA in coming weeks.
Live Audio Webcast Will be on February 15, 2018
Conference Call and Webcast Scheduled for Tuesday, February 13
- Total Preliminary Revenue for the Fourth Quarter of 2017 was Approximately $94 Million and $161 Million for the Full-Year 2017
Live Audio Webcast Will be on January 8, 2018
Live Audio Webcast Will be on December 14, 2017
- INGREZZA (valbenazine) Capsules Taken Once-daily Improved Tardive Dyskinesia Symptoms in Patients and was Generally Well Tolerated in 52-week Trial
Data from the Open-label KINECT 4 Phase III Study to be Presented as an Oral Hot Topic
Live Audio Webcast Will be on November 28, 2017
Live Audio Webcast Will be on November 16, 2017
Technology and biotech companies seem to be among the big winners.
The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.
- In two extension studies, elagolix demonstrated sustained reduction in average monthly menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse
Live Audio Webcast Will be on November 8, 2017
- FDA grants priority review to medicines it determines have potential to provide significant improvements in the safety and effectiveness of the treatment of a serious disease
12-Week T-Force GOLD Study to Assess the Safety, Tolerability, Efficacy and Optimal Dose of INGREZZA in Pediatric Patients
Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...
The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 1,118,638 share increase in total short interest for Neurocrine Biosciences, Inc. , to 8,122,994, an increase of 15.97% since 05/31/2017.
Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.
